Silence Therapeutics plc
SLNCF
$2.00
$0.2514.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.71% | 29.49% | 23.54% | -15.11% | 40.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.71% | 29.49% | 23.54% | -15.11% | 40.70% |
| Cost of Revenue | -98.18% | -80.01% | -39.46% | -7.67% | -5.69% |
| Gross Profit | -98.91% | 169.98% | 72.39% | -18.31% | 72.58% |
| SG&A Expenses | -16.88% | -8.93% | 3.81% | 14.05% | 4.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.76% | 27.09% | 45.59% | 38.16% | 13.07% |
| Operating Income | -65.97% | -26.23% | -56.13% | -81.95% | 3.47% |
| Income Before Tax | -99.26% | 1.74% | -81.66% | -82.55% | 14.77% |
| Income Tax Expenses | -98.70% | -96.56% | -94.23% | -86.34% | -26.95% |
| Earnings from Continuing Operations | -95.57% | 14.04% | -58.30% | -65.38% | 15.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -95.57% | 14.04% | -58.30% | -65.38% | 15.04% |
| EBIT | -65.97% | -26.23% | -56.13% | -81.95% | 3.47% |
| EBITDA | -66.85% | -26.54% | -56.93% | -83.25% | 3.48% |
| EPS Basic | -93.41% | 18.64% | -39.33% | -33.28% | 32.33% |
| Normalized Basic EPS | -94.20% | 6.96% | -58.08% | -45.55% | 32.86% |
| EPS Diluted | -93.41% | 18.64% | -39.33% | -33.28% | 32.33% |
| Normalized Diluted EPS | -94.20% | 6.96% | -58.08% | -45.55% | 32.86% |
| Average Basic Shares Outstanding | 2.13% | 6.93% | 13.08% | 20.41% | 24.68% |
| Average Diluted Shares Outstanding | 2.13% | 6.93% | 13.08% | 20.41% | 24.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |